Factors conditioning P2Y12 inhibitor choice after an acute coronary syndrome

被引：0
|
作者：
Fernando Fonseca Goncalves, F. [1 ]
Borges, S. C. [1 ]
Monteiro, J. J. [1 ]
Mateus, P. S. [1 ]
Moreira, J. I. [1 ]
机构：
[1] Hosp Ctr Tras Os Montes & Alto Douro, Cardiol, Vila Real, Portugal
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1367
引用
收藏
页码：245 / 245
页数：1
相关论文
共 50 条
  • [31] Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
    Song, Kai
    Jin, Xuan
    Kim, Moo-Hyun
    Li, Jia-Xin
    Jin, Cai-De
    Yuan, Song-Lin
    Song, Zhao-Yan
    Jin, En-Ze
    Lee, Kwang-Min
    Lim, Kyung-Hee
    Cho, Young-Rak
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [32] P2Y12 antagonists in acute coronary syndrome: In whom should they be started, and when?
    Good C.W.
    Berger P.B.
    Current Cardiology Reports, 2011, 13 (4) : 320 - 326
  • [33] A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs
    Wei Eric Wang
    Hongyong Wang
    Xukai Wang
    Chunyu Zeng
    Journal of Thrombosis and Thrombolysis, 2014, 37 : 102 - 106
  • [34] The Role of Direct-Acting P2Y12 Inhibitors in Acute Coronary Syndrome
    Buryakina, T. A.
    Zateyshchikov, D. A.
    KARDIOLOGIYA, 2012, 52 (04) : 74 - 79
  • [35] Meta-Analysis Comparing P2Y12 Inhibitors in Acute Coronary Syndrome
    Baldetti, Luca
    Melillo, Francesco
    Moroni, Francesco
    Gallone, Guglielmo
    Pagnesi, Matteo
    Venuti, Angela
    Beneduce, Alessandro
    Calvo, Francesco
    Gramegna, Mario
    Godino, Cosmo
    D'Ascenzo, Fabrizio
    De Ferrari, Gaetano M.
    Capodanno, Davide
    Cappelletti, Alberto M.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (12): : 1815 - 1822
  • [36] Novel Platelet ADP P2Y12 Inhibitors in the Treatment of Acute Coronary Syndrome
    Tan, Guang-Ming
    Lam, Yat-Yin
    Yan, Bryan P.
    CARDIOVASCULAR THERAPEUTICS, 2012, 30 (04) : e167 - e173
  • [37] A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs
    Wang, Wei Eric
    Wang, Hongyong
    Wang, Xukai
    Zeng, Chunyu
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 37 (02) : 102 - 106
  • [38] P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome
    Crouch, Michael A.
    Colucci, Vince J.
    Howard, Patricia A.
    Spinler, Sarah A.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (09) : 1151 - 1156
  • [39] Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?
    De Caterina, Raffaele
    Veneri, Alessia Delli
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (06) : 319 - 321
  • [40] Switching of P2Y12 inhibitor in patients with acute coronary syndrome: Insights from the GReek AntiPlatElet Registry (GRAPE)
    Xanthopoulou, I.
    Perperis, A.
    Stavrou, K.
    Siapika, A.
    Ntalas, I.
    Petousis, S.
    Angelidis, C.
    Parissis, H.
    Alexopoulos, D.
    EUROPEAN HEART JOURNAL, 2013, 34 : 884 - 885
12345